Literature DB >> 3951793

The place of sodium hyaluronate in glaucoma surgery.

R P Wilson, J Lloyd.   

Abstract

The advantages of sodium hyaluronate (Healon) in filtering surgery have been mostly theoretical, with no study of sufficient numbers to justify its use. The authors used sodium hyaluronate in 119 consecutive trabeculectomies. These were compared to a control group of 122 cases. The long-term intraocular pressure and visual acuity results between the two groups were indistinguishable. The only definite benefit noted with the use of sodium hyaluronate was the lower incidence of hyphemas. No side-effects were seen. Its ability to maintain a deep anterior chamber and encourage hemostasis makes sodium hyaluronate useful in teaching goniotomies as well as performing trabeculectomies in congenital glaucoma. Sodium hyaluronate can also be used to evacuate hyphemas and dissect adhesions with minimal trauma, and may be healthier for the corneal endothelium than air in anterior chamber reformations.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3951793

Source DB:  PubMed          Journal:  Ophthalmic Surg        ISSN: 0022-023X


  4 in total

1.  Glaucoma filtering surgery, a retrospective study of 300 operations.

Authors:  E Veldman; E L Greve
Journal:  Doc Ophthalmol       Date:  1987 Sep-Oct       Impact factor: 2.379

Review 2.  Hyaluronic acid. A review of its pharmacology and use as a surgical aid in ophthalmology, and its therapeutic potential in joint disease and wound healing.

Authors:  K L Goa; P Benfield
Journal:  Drugs       Date:  1994-03       Impact factor: 9.546

3.  Use of viscoelastic substance in ophthalmic surgery - focus on sodium hyaluronate.

Authors:  Tomomi Higashide; Kazuhisa Sugiyama
Journal:  Clin Ophthalmol       Date:  2008-03

4.  Hyphema is a risk factor for failure of trabeculectomy in neovascular glaucoma: a retrospective analysis.

Authors:  Shunji Nakatake; Shigeo Yoshida; Shintaro Nakao; Ryoichi Arita; Miho Yasuda; Takeshi Kita; Hiroshi Enaida; Yuji Ohshima; Tatsuro Ishibashi
Journal:  BMC Ophthalmol       Date:  2014-04-26       Impact factor: 2.209

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.